Now that federal lobbying data from the second quarter of the year is available to retrieve, we present our regular update on the state of activity across psychedelic drug developers and nonprofits. Psychedelics companies’ spending on lobbying firms at the federal level reached new heights in Q2 2026, though the aggregate amount (just shy of $350,000) remains relatively modest compared to…
